Minjuvi (Tafasitamab) Approved For Marketing In Mexico Brings New Hope To Patients with Refractory Lymphoma
March 2025 Knight Therapeutics announced that its anti-CD19 monoclonal antibody drug Minjuvi (tafasitamab) has been officially marketed in Mexico.
For the treatment of adult patients who are not candidates for autologous hematopoietic stem cell transplantation (ASCT) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
According to the 2025 National Comprehensive Cancer Network (NCCN) guidelines, Minjuvi is listed as a preferred second-line treatment option for patients with DLBCL who are not suitable for transplantation.
Minjuvi Clinical Trial
Minjuvi, initially used in combination with lenalidomide followed by single-agent maintenance therapy, offers a new treatment option for patients for whom conventional therapies have failed and stem cell transplantation is not possible.
The drug’s approval was based on the results of the L-MIND study, a multicenter, open-label Phase 2 clinical trial that evaluated the efficacy of tafasitamab in combination with lenalidomide in patients with relapsed or refractory DLBCL.
The study showed an overall remission rate of 60 percent, with a complete remission rate of 43 percent and a disease control rate of 74 percent.
Samira Sakhia, president and chief executive officer of Knight Therapeutics, said, “Minjuvi is an innovative product with clinical significance, and we are pleased to introduce it to Mexico and look forward to further expanding its accessibility in Latin America.”
New Treatment Options
DLBCL is the most common subtype of non-Hodgkin’s lymphoma with aggressive clinical features.
While many patients can achieve cure with first-line therapy, a significant number of patients relapse or become resistant to treatment after an initial response.
These patients are usually not candidates for ASCT and have a poor prognosis, so there is an urgent need for new treatment options to improve outcomes.
The launch of Minjuvi in Mexico is part of a collaboration between Knight Therapeutics and Incyte to expand the drug’s accessibility in Latin America.
Technological Breakthrough: More Efficient And Smarter AI models
Minjuvi says its newly developed algorithms have excelled in a number of benchmarks, outperforming current mainstream models, particularly in understanding complex semantics and contextual reasoning.
Kim Ji-hoon, the company’s CEO, said at the launch, “Our technology not only improves the responsiveness of AI, but also dramatically reduces the consumption of computational resources, which will enable more businesses and individuals to efficiently utilize AI capabilities.”
Future Plans
Minjuvi plans to launch its first commercialized product based on the technology early next year and gradually expand into the global market.
In addition, the company revealed that it is exploring in-depth cooperation with industries such as healthcare and finance to further unleash the potential of AI.
Founded in 2020, Minjuvi is an innovative company focused on the development of AI technology, headquartered in Seoul, South Korea, with an R&D center in Silicon Valley.
The company is committed to creating smarter and more humanized AI solutions to promote technology inclusion.
About DengYueMed – HK Drug Wholesale Distributor
As a legally compliant drug import and export company, DengYueMed is certified by the pharmacy & poisons board of Hong Kong — you can verify our qualification on their official website.
Our efforts to improve the affordability of tafasitamab-cxix drug aim to ensure that more patients can benefit from this important medication.
HK DengYue provides detailed medicine information, transparent pricing, and responsive support to ensure a smooth and reliable buying experience.
Feel free to reach out anytime to discuss your needs or ask questions about the medicine. We welcome you to contact us for a consultation.
